TMEM132A

Across TCGA pan-cancer cohorts, TMEM132A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM132A data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM132A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM132A expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCS show a favorable association.

HNSC, LIHC, and DLBC are the cancer types where TMEM132A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.170	0.698	<.001	38	view →
LIHC	OS	Median	All	0.280	0.784	<.001	33	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
SKCM	OS	Median	II,III,IV	0.908	0.718	.022	3	view →
LUAD	DFS	Median	All	0.143	0.355	.037	3	view →
UCS	DFS	Median	All	1.000	0.224	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM132A–HNSC (DFS)

Open the HNSC breakdown →